Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. The Company's ZYN002 is the synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear, odorless gel that is designed to provide controlled drug delivery with once- or twice-daily dosing. The Company's ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The transdermal patch is a non-invasive and non-oral dosage form of method of delivery. ZYN001 is a pro-drug, which is a drug administered in an inactive or less active form.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZYNE
  • CUSIP:
Key Metrics:
  • Previous Close: $8.98
  • 50 Day Moving Average: $8.8053
  • 200 Day Moving Average: $8.4559
  • 52-Week Range: $4.64 - $33.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.74
  • P/E Growth: 0.0000
  • Market Cap: $82.61M
  • Outstanding Shares: 9,199,000
Additional Links:
Companies Related to Zynerba Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.60 (263.03% upside)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2016Canaccord GenuityReiterated RatingBuy$35.00View Rating Details
8/12/2016Piper Jaffray Cos.Reiterated RatingOverweight$42.00View Rating Details
6/28/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$29.00View Rating Details
4/7/2016Jefferies GroupReiterated RatingBuy$32.00View Rating Details
3/17/2016Roth CapitalInitiated CoverageBuy$25.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/11/2016Q2($0.53)($0.70)ViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)ViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)ViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Current Year EPS Consensus Estimate: $-2.5400 EPS
Next Year EPS Consensus Estimate: $-2.4000 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.51)($0.43)($0.47)
Q2 20162($0.51)($0.48)($0.50)
Q3 20162($0.56)($0.54)($0.55)
Q4 20162($0.65)($0.54)($0.60)
Q1 20171($0.66)($0.66)($0.66)
Q2 20171($0.66)($0.66)($0.66)
Q3 20171($0.36)($0.36)($0.36)
Q4 20171($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateHeadline
News IconGlobal Fibromyalgia Pipeline Landscape and Therapeutics Development Market H2 2016 (NASDAQ:ZYNE)
www.khq.com - August 30 at 11:42 AM
News IconWhat's Smoking In The Legal Pot? (NASDAQ:ZYNE)
www.finanzen.ch - August 29 at 8:22 PM
live-pr.com logoNewly released market study: Zynerba Pharmaceuticals, Inc. (ZYNE) - Financial and Strategic SWOT Analysis Review (NASDAQ:ZYNE)
www.live-pr.com - August 25 at 8:40 PM
News IconHow is the Crowd Rating Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Shares? - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - August 25 at 5:12 AM
finance.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Financials (NASDAQ:ZYNE)
finance.yahoo.com - August 19 at 8:14 PM
News IconWhat is Wall Street Saying About Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? - Post News (NASDAQ:ZYNE)
www.kentuckypostnews.com - August 18 at 8:38 PM
streetinsider.com logoForm 4 Zynerba Pharmaceuticals, For: Aug 05 Filed by: Hanlon Suzanne M. (NASDAQ:ZYNE)
www.streetinsider.com - August 17 at 8:45 PM
News IconZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Is Executing On An Agressive Clinical Strategy (NASDAQ:ZYNE)
streetregister.com - August 17 at 11:26 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors (NASDAQ:ZYNE)
biz.yahoo.com - August 16 at 11:48 AM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ZYNE)
biz.yahoo.com - August 11 at 9:04 PM
reuters.com logoBRIEF-Zynerba Pharmaceuticals reported Q2 EPS ($0.70) - Reuters (NASDAQ:ZYNE)
www.reuters.com - August 11 at 11:56 AM
sg.finance.yahoo.com logoZynerba reports 2Q loss (NASDAQ:ZYNE)
sg.finance.yahoo.com - August 11 at 11:56 AM
publicnow.com logoZynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes (NASDAQ:ZYNE)
www.publicnow.com - August 11 at 11:56 AM
newsmaker.com.au logo2016 Pipeline of Alcohol Addiction Market Therapeutics Under Development Research (NASDAQ:ZYNE)
www.newsmaker.com.au - August 4 at 8:55 PM
nasdaq.com logoZynerba Pharmaceuticals to Present at Canaccord Genuity's 36th ... - Nasdaq (NASDAQ:ZYNE)
www.nasdaq.com - August 3 at 8:51 PM
finance.yahoo.com logoZynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference (NASDAQ:ZYNE)
finance.yahoo.com - August 3 at 11:46 AM
nasdaq.com logoZynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN0 (NASDAQ:ZYNE)
www.nasdaq.com - August 2 at 5:22 AM
investors.com logoZynerba doses first patient in epilepsy gel trial (NASDAQ:ZYNE)
www.proactiveinvestors.com - August 1 at 8:11 PM
finance.yahoo.com logoZynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 … (NASDAQ:ZYNE)
finance.yahoo.com - August 1 at 8:11 PM
News IconLearn details of the neuropathic pain pipeline products, key players involved and enlists all their major and minor projects (NASDAQ:ZYNE)
www.whatech.com - July 28 at 11:50 AM
News IconAre Analysts Bullish Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) After Last Week? - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - July 23 at 9:31 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - TGP (NASDAQ:ZYNE)
telanaganapress.com - July 22 at 11:23 AM
News IconCan Zynerba Pharmaceuticals Inc's Tomorrow Be Different? The Stock Increases Again - Consumer Eagle (NASDAQ:ZYNE)
www.consumereagle.com - July 22 at 11:23 AM
News IconTracking Analyst Ratings and Target Projections for: Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - July 20 at 9:36 PM
News IconStock Moving Lower for the Month; Investor Update on Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily (NASDAQ:ZYNE)
www.engelwooddaily.com - July 20 at 11:21 AM
News IconZynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ZYNE)
www.engelwooddaily.com - July 19 at 8:39 PM
News IconTrading Performance and Target Watch for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - July 18 at 5:17 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard (NASDAQ:ZYNE)
www.fiscalstandard.com - July 18 at 5:17 AM
News IconHow Analysts Rated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Last Week? - Consumer Eagle (NASDAQ:ZYNE)
www.consumereagle.com - July 16 at 11:36 AM
News IconAnalyst Target and Average Rating Watch: Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - July 14 at 8:42 PM
News IconCrowd Rating and Earnings Recap for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Telanagana Press (NASDAQ:ZYNE)
telanaganapress.com - July 14 at 8:42 PM
News IconZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ZYNE)
www.engelwooddaily.com - July 12 at 8:42 PM
finance.yahoo.com logoZynerba Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - Yahoo Finance (NASDAQ:ZYNE)
finance.yahoo.com - July 8 at 8:22 PM
News IconIncreased Volatility Watch for: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily (NASDAQ:ZYNE)
www.engelwooddaily.com - July 7 at 11:07 AM
nasdaq.com logoZynerba Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - Nasdaq (NASDAQ:ZYNE)
www.nasdaq.com - July 7 at 11:07 AM
publicnow.com logoZynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference (NASDAQ:ZYNE)
www.publicnow.com - July 6 at 7:31 AM
streetinsider.com logoForm 8-K Zynerba Pharmaceuticals, For: Jul 05 (NASDAQ:ZYNE)
www.streetinsider.com - July 5 at 8:01 PM
News IconCompany Stock Lower on the Week Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily (NASDAQ:ZYNE)
www.engelwooddaily.com - July 4 at 5:13 AM
fiscalstandard.com logoBrokers Issue Average Price Target Of 33.60 On Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard (NASDAQ:ZYNE)
www.fiscalstandard.com - June 29 at 8:22 PM
streetinsider.com logoZynerba Pharma (ZYNE) Reports Positive Top Line Results from ZYN002 CBD Gel Phase 1, Plans Phase 2 Study (NASDAQ:ZYNE)
www.streetinsider.com - June 29 at 11:07 AM
News IconZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:ZYNE)
www.engelwooddaily.com - June 28 at 8:25 PM
News IconShare Update and Earnings Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - June 28 at 8:25 PM
biz.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ZYNE)
biz.yahoo.com - June 28 at 6:02 AM
News IconStock Volatility in Review: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily (NASDAQ:ZYNE)
www.engelwooddaily.com - June 28 at 5:16 AM
News IconEquity Research and Technical Review on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - June 28 at 5:16 AM
publicnow.com logoZynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures (NASDAQ:ZYNE)
www.publicnow.com - June 27 at 4:31 PM
feeds.benzinga.com logo15 Stocks Moving In Monday's Pre-Market Session (NASDAQ:ZYNE)
feeds.benzinga.com - June 27 at 9:00 AM
fiscalstandard.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:ZYNE)
www.fiscalstandard.com - June 27 at 5:01 AM
fiscalstandard.com logoRecently Issued Stock Ratings For Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard (NASDAQ:ZYNE)
www.fiscalstandard.com - June 24 at 8:25 PM
News IconShare Volatility Check for: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Press Telegraph (NASDAQ:ZYNE)
presstelegraph.com - June 24 at 8:25 PM

Social

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff